HLA-A*02 Positive is an inclusion criterion in 13 clinical trials for melanoma, of which 10 are open and 3 are closed. Of the trials that contain HLA-A*02 Positive and melanoma as inclusion criteria, 1 is early phase 1 (0 open), 4 are phase 1 (3 open), 3 are phase 1/phase 2 (3 open), and 5 are phase 2 (4 open) [5].

HLA-A*02 Positive is altered in 0.06% of breast carcinoma patients [4].

HLA-A*02 Positive is an inclusion criterion in 6 clinical trials for breast carcinoma, of which 3 are open and 3 are closed. Of the trials that contain HLA-A*02 Positive and breast carcinoma as inclusion criteria, 4 are phase 1 (2 open) and 2 are phase 2 (1 open) [5].

HLA-A*02 Positive is altered in 0.11% of non-small cell lung carcinoma patients [4].

HLA-A*02 Positive is an inclusion criterion in 5 clinical trials for non-small cell lung carcinoma, of which 5 are open and 0 are closed. Of the trials that contain HLA-A*02 Positive and non-small cell lung carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 4 clinical trials for acute myeloid leukemia, of which 3 are open and 1 is closed. Of the trials that contain HLA-A*02 Positive and acute myeloid leukemia as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [5].

HLA-A*02 Positive is an inclusion criterion in 3 clinical trials for glioblastoma, of which 1 is open and 2 are closed. Of the trials that contain HLA-A*02 Positive and glioblastoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 2 (1 open), and 1 is phase 3 (0 open) [5].

HLA-A*02 Positive is an inclusion criterion in 3 clinical trials for hepatocellular carcinoma, of which 2 are open and 1 is closed. Of the trials that contain HLA-A*02 Positive and hepatocellular carcinoma as inclusion criteria, 3 are phase 1/phase 2 (2 open) [5].

HLA-A*02 Positive is an inclusion criterion in 3 clinical trials for multiple myeloma, of which 2 are open and 1 is closed. Of the trials that contain HLA-A*02 Positive and multiple myeloma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [5].

HLA-A*02 Positive is an inclusion criterion in 3 clinical trials for synovial sarcoma, of which 2 are open and 1 is closed. Of the trials that contain HLA-A*02 Positive and synovial sarcoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 2 clinical trials for anal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HLA-A*02 Positive and anal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].

HLA-A*02 Positive is an inclusion criterion in 2 clinical trials for cervical carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HLA-A*02 Positive and cervical carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].

HLA-A*02 Positive is an inclusion criterion in 2 clinical trials for chronic myeloid leukemia, of which 1 is open and 1 is closed. Of the trials that contain HLA-A*02 Positive and chronic myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].

HLA-A*02 Positive is an inclusion criterion in 2 clinical trials for gastric carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HLA-A*02 Positive and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

HLA-A*02 Positive is altered in 0.06% of malignant solid tumor patients [4].

HLA-A*02 Positive is an inclusion criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain HLA-A*02 Positive and malignant solid tumor as inclusion criteria, 2 are phase 1 (2 open) [5].

HLA-A*02 Positive is an inclusion criterion in 2 clinical trials for myelodysplastic syndromes, of which 1 is open and 1 is closed. Of the trials that contain HLA-A*02 Positive and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].

HLA-A*02 Positive is an inclusion criterion in 2 clinical trials for myxoid liposarcoma, of which 2 are open and 0 are closed. Of the trials that contain HLA-A*02 Positive and myxoid liposarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 2 clinical trials for oropharyngeal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HLA-A*02 Positive and oropharyngeal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].

HLA-A*02 Positive is an inclusion criterion in 2 clinical trials for oropharyngeal squamous cell carcinoma, of which 0 are open and 2 are closed. Of the trials that contain HLA-A*02 Positive and oropharyngeal squamous cell carcinoma as inclusion criteria, 2 are phase 2 (0 open) [5].

HLA-A*02 Positive is an inclusion criterion in 2 clinical trials for pancreatic ductal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain HLA-A*02 Positive and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 0 are open and 1 is closed. Of the trial that contains HLA-A*02 Positive and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for adrenal cortex carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and adrenal cortex carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for adrenal gland pheochromocytoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and adrenal gland pheochromocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for chronic lymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains HLA-A*02 Positive and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for diffuse astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and diffuse astrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for ductal carcinoma in situ, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and ductal carcinoma in situ as inclusion criteria, 1 is phase 2 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and esophageal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HLA-A*02 Positive is altered in 0.07% of glioma patients [4].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for hepatoblastoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and hepatoblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains HLA-A*02 Positive and hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for leptomeningeal melanoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and leptomeningeal melanoma as inclusion criteria, 1 is phase 2 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for liver neoplasm, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and liver neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

HLA-A*02 Positive is altered in 0.2% of low grade glioma patients [4].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for low grade glioma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and low grade glioma as inclusion criteria, 1 is phase 2 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for malignant head and neck neoplasm, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and malignant head and neck neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

HLA-A*02 Positive is altered in 0.05% of malignant ovarian neoplasm patients [4].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for malignant ovarian neoplasm, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and malignant ovarian neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-1, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 1 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 1 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and myelofibrosis as inclusion criteria, 1 is phase 1 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains HLA-A*02 Positive and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for oligoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and oligoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for oral cavity squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and oral cavity squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for paraganglioma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and paraganglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and penile carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for refractory anemia with excess blasts, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and refractory anemia with excess blasts as inclusion criteria, 1 is phase 1 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for round cell liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and round cell liposarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for smoldering plasma cell myeloma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and smoldering plasma cell myeloma as inclusion criteria, 1 is phase 1 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for uveal melanoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and uveal melanoma as inclusion criteria, 1 is phase 2 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and vaginal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

HLA-A*02 Positive is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02 Positive and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].